Alaa Harb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alaa Harb has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Juliana Nery Souza-Talarico
College of Nursing University of Iowa Iowa City Iowa USA
4 shared publications - Hans-Joachim Lehmler
Department of Occupational and Environmental Health, University of Iowa, Iowa City, Iowa, USA
2 shared publications - Jennifer DeBerg
Hardin Library for the Health Sciences, University of Iowa, Iowa City, IA
2 shared publications - Katherine Carroll Britt
College of Nursing, University of Iowa, Iowa City, IA 52242, USA
2 shared publications - Maria Hein
College of Nursing, University of Iowa, Iowa City, IA
2 shared publications - Sena Chae
College of Nursing The University of Iowa Iowa City Iowa USA
2 shared publications
Latest Publications
- Open Access
Navigating Life After Dementia Diagnosis: Questions, Challenges, and Support Needs Among Dementia Dyads
Background: Older adults living with mild cognitive impairment (MCI) or Alzheimer’s disease and related dementias (AD/ADRD) and their care partners face substantial daily challenges that evolve with disease progression and extend far beyond the clinical setting, including symptom management, care coordination, healthcare navigation, and planning for future care needs. Understanding these challenges is essential for developing innovative solutions to provide ongoing and targeted support. In this study, we explored questions, challenges, and support needs dementia dyads experienced following diagnosis to inform the development of an artificial intelligence (AI)-based chatbot designed to provide ongoing support for dementia dyads. Methods: We recruited 11 community-dwelling dyads comprising persons living with MCI or mild AD/ADRD and their care partners, one additional care partner, and 12 dementia care experts from academic medical centers, clinics, and aging organizations in the U.S. We conducted semi-structured interviews and analyzed them using conventional content analysis. Results: Participants described interconnected questions, challenges, and support needs that evolved while navigating life with MCI or AD/ADRD. Questions centered around day-to-day care management, medical concerns, behavioral symptom management, diagnosis and prognosis, safety, and resources and services. Challenges included care partner overwhelm, limited dementia knowledge, condition-related uncertainty, healthcare system navigation difficulties, financial constraints, and technology-related barriers. Participants identified needs for ongoing education, personalized care planning, resource navigation, logistical support and follow-up, culturally responsive care, and social and emotional support. Conclusions: Dementia dyads experience substantial informational, emotional, and practical support needs in the early stages of MCI and AD/ADRD. Findings suggest that post-diagnostic support should extend beyond information provision alone to provide ongoing, personalized, and practical guidance that helps dyads navigate changing needs, resources, and everyday dementia care. These findings are informing the development of an AI-based chatbot intended to complement existing dementia care by extending access to education, practical guidance, and resource navigation between clinical encounters.
Open AccessNavigating Life After Dementia Diagnosis: Questions, Challenges, and Support Needs Among Dementia Dyads
Background: Older adults living with mild cognitive impairment (MCI) or Alzheimer’s disease and related dementias (AD/ADRD) and their care partners face substantial daily challenges that evolve with disease progression and extend far beyond the clinical setting, including symptom management, care coordination, healthcare navigation, and planning for future care needs. Understanding these challenges is essential for developing innovative solutions to provide ongoing and targeted support. In this study, we explored questions, challenges, and support needs dementia dyads experienced following diagnosis to inform the development of an artificial intelligence (AI)-based chatbot designed to provide ongoing support for dementia dyads. Methods: We recruited 11 community-dwelling dyads comprising persons living with MCI or mild AD/ADRD and their care partners, one additional care partner, and 12 dementia care experts from academic medical centers, clinics, and aging organizations in the U.S. We conducted semi-structured interviews and analyzed them using conventional content analysis. Results: Participants described interconnected questions, challenges, and support needs that evolved while navigating life with MCI or AD/ADRD. Questions centered around day-to-day care management, medical concerns, behavioral symptom management, diagnosis and prognosis, safety, and resources and services. Challenges included care partner overwhelm, limited dementia knowledge, condition-related uncertainty, healthcare system navigation difficulties, financial constraints, and technology-related barriers. Participants identified needs for ongoing education, personalized care planning, resource navigation, logistical support and follow-up, culturally responsive care, and social and emotional support. Conclusions: Dementia dyads experience substantial informational, emotional, and practical support needs in the early stages of MCI and AD/ADRD. Findings suggest that post-diagnostic support should extend beyond information provision alone to provide ongoing, personalized, and practical guidance that helps dyads navigate changing needs, resources, and everyday dementia care. These findings are informing the development of an AI-based chatbot intended to complement existing dementia care by extending access to education, practical guidance, and resource navigation between clinical encounters.
- 22 July 2026
- Published by Wolters Kluwer Health in Cancer Nursing
Clinical Perspectives on Actionable Risk Factors for Deterioration in Acute Myeloid Leukemia: Implications for Clinical Decision Support
Background: Acute myeloid leukemia (AML) is associated with high complication rates following induction chemotherapy, yet clinicians lack tools that anticipate deterioration and support proactive care. Preliminary predictive modeling using structured electronic health record data and symptoms extracted through natural language processing identified key risk factors for deterioration within 30 days of discharge. How clinicians interpret these risk factors in practice remains unclear. Objective: This study aimed to explore how hematology clinicians understand actionable risk factors for deterioration in AML and how these factors should inform the design of clinical decision support. Interventions/Methods: Seven hematology clinicians—including hematologist-oncologists, a nurse practitioner, and physician assistants—at a Midwestern academic medical center participated in individual or group semistructured interviews. Interview questions addressed perceived risk factors, actionability, and needs for clinical decision support. Data were analyzed using conventional content analysis. Results: Three themes emerged: (1) generic tools do not adequately support the complexity of AML care; (2) actionability is context‑dependent, with both nonmodifiable and modifiable factors influencing discharge decision‑making; and (3) clinical decision support must integrate predictive risk scoring with user‑centered design features such as intuitive displays, timely alerts, and transparency about contributing factors. Conclusions: Clinicians expressed strong support for a clinical decision support tool that anticipates deterioration, provides individualized and interpretable risk alerts, and aligns with existing workflows to reduce preventable complications and readmissions. Implications for Oncology Nursing Practice: Clinical decision support tools that integrate dynamic clinical data with intuitive, workflow‑aligned interfaces may enhance risk communication, strengthen discharge decision‑making, and support proactive monitoring in AML care.
- 22 July 2026
- Published by Wolters Kluwer Health in Cancer Nursing
Clinical Perspectives on Actionable Risk Factors for Deterioration in Acute Myeloid Leukemia: Implications for Clinical Decision Support
Background: Acute myeloid leukemia (AML) is associated with high complication rates following induction chemotherapy, yet clinicians lack tools that anticipate deterioration and support proactive care. Preliminary predictive modeling using structured electronic health record data and symptoms extracted through natural language processing identified key risk factors for deterioration within 30 days of discharge. How clinicians interpret these risk factors in practice remains unclear. Objective: This study aimed to explore how hematology clinicians understand actionable risk factors for deterioration in AML and how these factors should inform the design of clinical decision support. Interventions/Methods: Seven hematology clinicians—including hematologist-oncologists, a nurse practitioner, and physician assistants—at a Midwestern academic medical center participated in individual or group semistructured interviews. Interview questions addressed perceived risk factors, actionability, and needs for clinical decision support. Data were analyzed using conventional content analysis. Results: Three themes emerged: (1) generic tools do not adequately support the complexity of AML care; (2) actionability is context‑dependent, with both nonmodifiable and modifiable factors influencing discharge decision‑making; and (3) clinical decision support must integrate predictive risk scoring with user‑centered design features such as intuitive displays, timely alerts, and transparency about contributing factors. Conclusions: Clinicians expressed strong support for a clinical decision support tool that anticipates deterioration, provides individualized and interpretable risk alerts, and aligns with existing workflows to reduce preventable complications and readmissions. Implications for Oncology Nursing Practice: Clinical decision support tools that integrate dynamic clinical data with intuitive, workflow‑aligned interfaces may enhance risk communication, strengthen discharge decision‑making, and support proactive monitoring in AML care.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3)
Early Unplanned Readmissions and Mortality After Induction Chemotherapy in AML
PURPOSE: AML is a highly aggressive hematologic cancer. During induction chemotherapy, up to 40% of patients experience complications resulting in unplanned readmissions or early death. This study aimed to identify the reasons for postinduction unplanned readmissions and to develop predictive models for unplanned readmissions or early death using structured and unstructured electronic health record (EHR) data to identify patients at highest risk. METHODS: We retrospectively analyzed 1,111 inpatient encounters from 305 adult patients with AML treated at a Midwestern university hospital between 2006 and 2021. Inclusion criterion was adults with AML undergoing induction chemotherapy; exclusion criteria included acute promyelocytic leukemia, stem cell transplant recipients, and confirmed chronic myeloid leukemia. Adverse events—unplanned readmissions or mortality within 30 days of discharge from the initial induction hospitalization—were identified through chart review using predefined rules. Multiple logistic regression was used to identify risk factors. Variable selection was performed using the least absolute shrinkage and selection operator. RESULTS: Within 30 days postdischarge, 22% of patients experienced an unplanned readmission. The most frequent reasons were fever/infection (53.5%), metabolic/GI/renal complications (16.2%), and pain/discomfort (14.1%). Mortality within 30 days was 22%. Predictive performance improved when comorbidities and symptom frequency from clinical notes were added (AUC increased from 0.67 to 0.74). Statistically significant predictors of increased adverse event risk included solid neoplasm (odds ratio [OR], 2.34), higher cardiopulmonary symptom burden per day (OR, 1.16), and a chemotherapy intensity moderated by age (OR, 0.90). CONCLUSION: Unplanned readmissions or early mortality occurred in 39.7% of patients with AML within 30 days postdischarge. Integrated risk stratification tools leveraging structured and unstructured EHR data may inform timely interventions to improve survival and reduce avoidable hospitalizations.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3)
Early Unplanned Readmissions and Mortality After Induction Chemotherapy in AML
PURPOSE: AML is a highly aggressive hematologic cancer. During induction chemotherapy, up to 40% of patients experience complications resulting in unplanned readmissions or early death. This study aimed to identify the reasons for postinduction unplanned readmissions and to develop predictive models for unplanned readmissions or early death using structured and unstructured electronic health record (EHR) data to identify patients at highest risk. METHODS: We retrospectively analyzed 1,111 inpatient encounters from 305 adult patients with AML treated at a Midwestern university hospital between 2006 and 2021. Inclusion criterion was adults with AML undergoing induction chemotherapy; exclusion criteria included acute promyelocytic leukemia, stem cell transplant recipients, and confirmed chronic myeloid leukemia. Adverse events—unplanned readmissions or mortality within 30 days of discharge from the initial induction hospitalization—were identified through chart review using predefined rules. Multiple logistic regression was used to identify risk factors. Variable selection was performed using the least absolute shrinkage and selection operator. RESULTS: Within 30 days postdischarge, 22% of patients experienced an unplanned readmission. The most frequent reasons were fever/infection (53.5%), metabolic/GI/renal complications (16.2%), and pain/discomfort (14.1%). Mortality within 30 days was 22%. Predictive performance improved when comorbidities and symptom frequency from clinical notes were added (AUC increased from 0.67 to 0.74). Statistically significant predictors of increased adverse event risk included solid neoplasm (odds ratio [OR], 2.34), higher cardiopulmonary symptom burden per day (OR, 1.16), and a chemotherapy intensity moderated by age (OR, 0.90). CONCLUSION: Unplanned readmissions or early mortality occurred in 39.7% of patients with AML within 30 days postdischarge. Integrated risk stratification tools leveraging structured and unstructured EHR data may inform timely interventions to improve survival and reduce avoidable hospitalizations.
- Open Access
PFAS exposure and neuroimmune and Alzheimers Disease related plasma biomarkers in a rural, cognitively unimpaired population: a pilot study
INTRODUCTION: Alzheimers disease (AD) is a multifactorial disorder, yet current research largely focuses on downstream biomarkers with limited attention to environmental contributors. Experimental studies suggest that per and polyfluoroalkyl substances (PFAS) may contribute to neuroimmune and neurodegenerative pathways relevant to AD. OBJECTIVE: To examine associations between PFAS exposure and neuroimmune and AD related plasma biomarkers in cognitively unimpaired rural adults. METHODS: In a cross sectional pilot study (n=48), serum concentrations of 33 PFAS were measured, including four legacy compounds (PFOS, PFHxS, PFOA, PFNA). Plasma neuroimmune related (ITGB2, SMOC1, TREM2, GFAP) and AD related biomarkers (Ab42/40, ptau217) were detected using proteomic analysis. RESULTS: PFOS showed moderate associations with ITGB2, SMOC1, and Ab42/40 in unadjusted analyses, which attenuated after adjustment for age. PFOA and PFNA demonstrated consistent inverse associations with TREM2 before and after adjustment. DISCUSSION: Findings suggest possible compound specific PFAS associations with immune and amyloid related biomarkers, supporting further investigation in longitudinal and PFAS mixture based studies.
Open AccessPFAS exposure and neuroimmune and Alzheimers Disease related plasma biomarkers in a rural, cognitively unimpaired population: a pilot study
INTRODUCTION: Alzheimers disease (AD) is a multifactorial disorder, yet current research largely focuses on downstream biomarkers with limited attention to environmental contributors. Experimental studies suggest that per and polyfluoroalkyl substances (PFAS) may contribute to neuroimmune and neurodegenerative pathways relevant to AD. OBJECTIVE: To examine associations between PFAS exposure and neuroimmune and AD related plasma biomarkers in cognitively unimpaired rural adults. METHODS: In a cross sectional pilot study (n=48), serum concentrations of 33 PFAS were measured, including four legacy compounds (PFOS, PFHxS, PFOA, PFNA). Plasma neuroimmune related (ITGB2, SMOC1, TREM2, GFAP) and AD related biomarkers (Ab42/40, ptau217) were detected using proteomic analysis. RESULTS: PFOS showed moderate associations with ITGB2, SMOC1, and Ab42/40 in unadjusted analyses, which attenuated after adjustment for age. PFOA and PFNA demonstrated consistent inverse associations with TREM2 before and after adjustment. DISCUSSION: Findings suggest possible compound specific PFAS associations with immune and amyloid related biomarkers, supporting further investigation in longitudinal and PFAS mixture based studies.
- Open Access
Operationalizing the neural exposome for brain health and Alzheimer’s Disease and Related Dementias (AD/ADRD) vulnerability in rural settings: pilot study
INTRODUCTION: Alzheimer’s disease and related dementias (AD/ADRD) arise from cumulative environmental, social, behavioral, and biological influences across the life course. The neural exposome framework conceptualizes how exogenous, behavioral, and endogenous factors interact to shape brain health; however, its application to preclinical AD/ADRD research, particularly in rural populations, remains limited. METHODS: We developed and piloted a community-embedded, decentralized research model to operationalize the neural exposome framework among cognitively unimpaired adults aged 45+ in two rural Midwestern U.S. communities, integrating environmental, social, behavioral, geospatial, and biological measures to evaluate exposure-related neurobiological and cognitive vulnerability. RESULTS: This approach demonstrated high feasibility and acceptability, achieving strong recruitment, retention, data completeness, and multidomain biomarker collection in rural community-based settings DISCUSSION: Pilot findings support the feasibility of neural exposome-informed research in rural U.S. communities and highlight its potential to advance prevention-oriented research on brain health and AD/ADRD.
Open AccessOperationalizing the neural exposome for brain health and Alzheimer’s Disease and Related Dementias (AD/ADRD) vulnerability in rural settings: pilot study
INTRODUCTION: Alzheimer’s disease and related dementias (AD/ADRD) arise from cumulative environmental, social, behavioral, and biological influences across the life course. The neural exposome framework conceptualizes how exogenous, behavioral, and endogenous factors interact to shape brain health; however, its application to preclinical AD/ADRD research, particularly in rural populations, remains limited. METHODS: We developed and piloted a community-embedded, decentralized research model to operationalize the neural exposome framework among cognitively unimpaired adults aged 45+ in two rural Midwestern U.S. communities, integrating environmental, social, behavioral, geospatial, and biological measures to evaluate exposure-related neurobiological and cognitive vulnerability. RESULTS: This approach demonstrated high feasibility and acceptability, achieving strong recruitment, retention, data completeness, and multidomain biomarker collection in rural community-based settings DISCUSSION: Pilot findings support the feasibility of neural exposome-informed research in rural U.S. communities and highlight its potential to advance prevention-oriented research on brain health and AD/ADRD.
- 4 December 2025
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 184, 107714
Discrimination and allostatic load in black middle-aged and older adults: A systematic review and meta-analysis
- 4 December 2025
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 184, 107714
Discrimination and allostatic load in black middle-aged and older adults: A systematic review and meta-analysis
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 19, e20240256
Loneliness during the COVID-19 pandemic: A potential risk factor for post-pandemic cognitive decline in older adults without dementia
The COVID-19 pandemic has exacerbated loneliness and social isolation among older adults, raising concerns about their mental and physical well-being. While loneliness’s adverse effects on health are well-documented, its specific impact on cognitive health during the pandemic remains under investigation. Objective: The aim of this study was to examine the association between loneliness during the COVID-19 pandemic and cognitive decline in cognitively unimpaired older adults by synthesizing evidence from primary studies. Methods: A comprehensive search strategy was employed across multiple databases, including MEDLINE (PubMed), CINAHL (EBSCO), PsycINFO (EBSCO), EMBASE, Scopus, AgeLine, and ProQuest, following PRISMA guidelines. Studies were selected to examine the association between loneliness and cognitive function in cognitively unimpaired older adults (aged ≥50 years) during the COVID-19 pandemic. Results: A total of eight studies were included from 1,384 search results, reviewing data from 10,449 cognitively unimpaired older adults. A total of six studies found significant associations between loneliness or social isolation and subjective cognitive decline (SCD). Only one study linked loneliness to lower objective cognitive performance. Notably, half of the studies considered key covariates, such as depression, which could mediate the relationship between loneliness and cognitive decline. Conclusion: Loneliness during the COVID-19 pandemic is linked to SCD in older adults, though objective evidence is limited. The pandemic underscored the long-term impact of social isolation on cognition and mental health, highlighting the need for standardized neuropsychological tools and key covariates in studies to identify those at risk.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 19, e20240256
Open AccessLoneliness during the COVID-19 pandemic: A potential risk factor for post-pandemic cognitive decline in older adults without dementia
The COVID-19 pandemic has exacerbated loneliness and social isolation among older adults, raising concerns about their mental and physical well-being. While loneliness’s adverse effects on health are well-documented, its specific impact on cognitive health during the pandemic remains under investigation. Objective: The aim of this study was to examine the association between loneliness during the COVID-19 pandemic and cognitive decline in cognitively unimpaired older adults by synthesizing evidence from primary studies. Methods: A comprehensive search strategy was employed across multiple databases, including MEDLINE (PubMed), CINAHL (EBSCO), PsycINFO (EBSCO), EMBASE, Scopus, AgeLine, and ProQuest, following PRISMA guidelines. Studies were selected to examine the association between loneliness and cognitive function in cognitively unimpaired older adults (aged ≥50 years) during the COVID-19 pandemic. Results: A total of eight studies were included from 1,384 search results, reviewing data from 10,449 cognitively unimpaired older adults. A total of six studies found significant associations between loneliness or social isolation and subjective cognitive decline (SCD). Only one study linked loneliness to lower objective cognitive performance. Notably, half of the studies considered key covariates, such as depression, which could mediate the relationship between loneliness and cognitive decline. Conclusion: Loneliness during the COVID-19 pandemic is linked to SCD in older adults, though objective evidence is limited. The pandemic underscored the long-term impact of social isolation on cognition and mental health, highlighting the need for standardized neuropsychological tools and key covariates in studies to identify those at risk.